Shares of Regeneron Pharmaceuticals sank sharply after the company announced that its Phase 3 trial testing fianlimab - a LAG-3 inhibitor - in combination with cemiplimab did not reach statistical significance for the trial's primary endpoint. The study evaluated the combination as a first-line treatment for unresectable or metastatic melanoma against pembrolizumab (Keytruda) monotherapy.
Although the combination showed a numeric improvement in median progression-free survival (PFS) of 5.1 months compared with Merck's Keytruda, the difference failed to attain statistical significance, with a reported p-value of 0.0627. The trial enrolled 1,546 patients across four arms and, despite the numerical gain, the lack of a statistically significant primary endpoint has driven investor concern.
Analyst and market reaction
The clinical outcome triggered immediate analyst responses. Citi downgraded Regeneron from Buy to Neutral and cut its price target from $900 to $700, explicitly removing the melanoma opportunity for fianlimab from its valuation. Both BMO and Evercore also removed fianlimab from their financial models following the Phase 3 setback.
In contrast, BofA Securities maintained a Buy rating with a $860.00 price target and did not assign standalone value to the program; BofA described share-price weakness as an attractive entry point. The divergence among firms highlights differing approaches to valuing the company in light of the clinical result.
Separately, Regeneron disclosed a research collaboration with Parabilis Medicines under which Parabilis will receive $125 million, including a $50 million upfront payment and a $75 million equity commitment. While this corporate transaction is a positive development, it was not sufficient to counter the negative market reaction to the Phase 3 outcome.
Stock movement and context
The initial reaction in morning trading saw Regeneron shares drop 11.06%. At the time referenced in the company update, REGN was trading at $621, well below the prior close of $698.25 and nearer the lower end of its 52-week range of $476.49 to $821.11. Earlier intraday data noted a price of $627.85 with a decline of $70.40, or -10.08% in real time; the broader U.S. market provided little shelter, with the S&P 500 essentially flat at -0.02%, the Dow Jones off -0.05%, and the NASDAQ down -0.04%.
Market observers attributed the steep decline to company-specific developments rather than general market weakness, pointing to the clinical disappointment and subsequent model adjustments by sell-side analysts as the primary drivers.
Pipeline pressure and remaining paths
The fianlimab setback compounds earlier pipeline challenges for Regeneron. Nearly a year earlier, Regeneron and Sanofi reported the failure of one of two Phase 3 trials for their IL-33 drug itepekimab in COPD. Those back-to-back misses in late-stage programs have heightened scrutiny over the company’s near-term clinical development outlook, which analysts say will face pressure over the next 12 to 18 months.
One remaining near-term avenue for fianlimab to regain investor confidence is an ongoing Phase 3 head-to-head trial comparing a high-dose fianlimab combination against Opdualag in first-line unresectable or metastatic melanoma. Until that readout, the Phase 3 miss reported here removes the primary positive evidence for the program in this indication.
Financial and valuation implications
Analysts had previously estimated the melanoma opportunity for fianlimab at roughly $2–3 billion in addressable market value. With the Phase 3 miss and multiple firms excising the program from their models, Regeneron's near-term valuation assumptions have shifted materially. The downgrade from Citi and the removal of the program by other analysts effectively lowered near-term expectations and helped drive the share-price move.
Investors and market participants will be watching the ongoing high-dose head-to-head study as the principal remaining clinical pathway for the program to demonstrate a differentiated benefit and to potentially restore value to prior estimates.
Summary
Regeneron's Phase 3 trial of fianlimab combined with cemiplimab missed its primary endpoint for progression-free survival versus pembrolizumab in first-line unresectable or metastatic melanoma, producing a numeric but not statistically significant median PFS improvement of 5.1 months (p=0.0627) across 1,546 patients in four arms. The clinical outcome led to analyst downgrades and removals of the program from valuation models, a corporate collaboration with Parabilis that provided limited offset, and a marked decline in the company’s stock price amid otherwise subdued broader market movement.